US Accounts for 50% of Global Cancer Vaccine Market
Upcoming SlideShare
Loading in...5
×
 

US Accounts for 50% of Global Cancer Vaccine Market

on

  • 27 views

“US Cancer Vaccine Market Outlook 2018” Research Report Highlight: ...

“US Cancer Vaccine Market Outlook 2018” Research Report Highlight:
 Marketed Cancer Vaccines: 9
 Cancer Vaccine Clinical Development: 157
 Skin Cancer Dominating Vaccine Clinical Pipeline
 Cancer Incidence & Prevalence
 Cancer Vaccine Market Overview
 Cancer Vaccine Pricing & Reimbursement Policy
 Cancer Vaccine with Orphan Status
 Cancer Vaccine Pipeline by Indication & Phase
 Market Regulations
 Company Overview & Vaccine Pipeline

Statistics

Views

Total Views
27
Views on SlideShare
27
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

US Accounts for 50% of Global Cancer Vaccine Market US Accounts for 50% of Global Cancer Vaccine Market Document Transcript

  • US Accounts for 50% of Global Cancer Vaccine Market US dominating the cancer vaccine market development landscape. “US Cancer Vaccine Market Outlook 2018” Research Report Highlight:  Marketed Cancer Vaccines: 9  Cancer Vaccine Clinical Development: 157  Skin Cancer Dominating Vaccine Clinical Pipeline  Cancer Incidence & Prevalence  Cancer Vaccine Market Overview  Cancer Vaccine Pricing & Reimbursement Policy  Cancer Vaccine with Orphan Status  Cancer Vaccine Pipeline by Indication & Phase  Market Regulations  Company Overview & Vaccine Pipeline The vaccine market, specifically the cancer vaccine market has remained resilient to the global economic crisis in contrast to many life science sectors, which were severely impacted. Owing to drying pipelines and increasing pressure from patent expirations, the big pharma companies recognized the vaccine market as a potential resource of investment. Cancer vaccines are known to earn a higher profit than the generic drugs, owing to the nature of the disease and the urgency in the demand for these vaccines. The US cancer vaccine market was estimated to be worth USD 14 billion in 2012. The market is expected to witness an increase of 1.5 million people being diagnosed with cancer annually. With such a rapid increase in the incidence, the US cancer vaccine market is expected to grow at a CAGR of 10% to reach USD 24.8 billion by 2018. The market for cancer vaccine is in its growth stage in the US and has great opportunities for entry. The USA alone accounts for a dominating share of 50% as compared to a combined share of 50% accounted for by Europe and other regions. For Report Sample Visit: US Cancer Vaccine Market Outlook 2018 Or Contact: avinash@kuickresearch.com